All News
Watch my interview w/incredible rheum leaders in the field of aging:
👉🏼what inspired them
👉🏼changes we need to make in our practice
👉🏼end of life care (including MD-assisted suicide).
#BetterThanNPR
#ACR21 @RheumNow
@UnaMakris
https://t.co/RBfvgHEkpm via @YouTube
TheDaoIndex KDAO2011 ( View Tweet)
GLORIA study of adding prednisolone 5mg to DMARDs over 2 years for RA in those >65 years. Mean DAS 0.37 points lower, Sharp score 1.7 lower (are either of these clinically significant?). NNH 9.5. To me causing harm chasing statistical benefit Abstr#1678 #ACR21 @RheumNow #ACRBest https://t.co/KYk1II3J3w
Richard Conway RichardPAConway ( View Tweet)
Avacopan effects on renal disease in AAV presented in further detail. Greater recovery with avacopan, which was accentuated in those with worse renal disease or proteinuria at baseline. Abstr#L14 #ACR21 @RheumNow https://t.co/dfTmhhsNnX
Richard Conway RichardPAConway ( View Tweet)
Clinical and research pearl: SPACC vs LEEDs enthesitis scoring for your PsA patients by Dr. Ogdie. #ACR21 @RheumNow #RheumNow https://t.co/dDznwSicRQ
Dr. Rachel Tate uptoTate ( View Tweet)
I don't know much about antifibrotics in RA-ILD, but these data emphasise that HRCT pattern matters
My simple mind, for any disease:
multiple subtypes with different trajectories➡️likely to be differing responses to Rx
TRAIL1: pirfenidone in RA-ILD
#ACR21 ABSTL10 @RheumNow https://t.co/v7HCO0ZBe1
David Liew drdavidliew ( View Tweet)
#SARSCoV2 infections in vaccinated pts w/ #rheumaticdisease @rheum_covid @rheum_cat
👉🏼Most pts with breakthrough infections were on anti-metabolites or B-cell depleting therapies
👉🏼Encourage patients to get their #BoosterShot!
Abs#L04 #ACR21 @RheumNow
https://t.co/TAB4zrjPN1 https://t.co/z0gpsxN3xc
Mrinalini Dey DrMiniDey ( View Tweet)
⬆HCQ blood levels significantly associated w/ ⬇ in mean SLEDAI, UPCR, SBP & platelet cts
🔷Assoc'n strongest in HCQ conc'n in range 0-1000ng/mL
A possible HCQ blood level target to ⬇ 👁toxicity?🤔
@RheumNow #ACR21 abs1753 https://t.co/3jkDDakIcb
sheila RHEUMarampa ( View Tweet)
Comparative effects of abatacept in RA-ILD with UIP/NSIP. Appears equally effective in stabilising FVC, DLCO, and HRCT findings in both. Abstr#1683 #ACR21 @RheumNow https://t.co/l0Ia1D9c56
Richard Conway RichardPAConway ( View Tweet)
Abst1510 #ACR21 @RheumNow in animal study Stimulation w/ SIINFEKL peptide induces proliferation of resident memory CD8+ T cells in target joint resulting in increased numbers of B cells, Neutrophils, and CD4 cells within the joint space =localized inflammatory arthritis https://t.co/QlYT8OyGTt
Olga Petryna DrPetryna ( View Tweet)
Interesting study on Pioglitazone significantly improving vascular stiffness and cardiometabolic parameters vs. PBO in #lupus by @sarfarazhasni et al.
Pioglitazone: potential tx option to reduce CV risk in SLE?🧐
@RheumNow #ACR21 abs1748 https://t.co/ow3zA2hhnx
sheila RHEUMarampa ( View Tweet)
ePROs for SpA patients showed a trend in reduction of disease activity, improved clinic workload, individualized treatment with good patient/physician user satisfaction
Abs#1788
#ACR21 @RheumNow
https://t.co/04kUikdIZu https://t.co/uO9junUqKi
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Sleep disturbance common and associated with disease activity (both PRO and physician-assessed) in RA. Need further studies to evaluate causal directions, but may well be bidirectional? Abstr#1666 #ACR21 @RheumNow https://t.co/eK65I92wPg
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1683: ABA for RA-ILD
⭐️Stabilization of DLCO, FVC, HRCT in UIP and NSIP in 106 UIP, 84 NSIP patients
⭐️Stabilization or improvement of dyspnea in 91% UIP, 95% NSIP pts
@Rheumnow https://t.co/qfgDmooGOj https://t.co/gz6Jk15nUs
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#1699: ITIS diet:
⭐️Fatigue ⬇️ in 20 pts on ITIS trial, didn't correlate with final DAS28CRP
⭐️Fatigue responders (50% improvement) had different fecal microbiome changes & anti-inflamm compounds, than non-responders
@Rheumnow https://t.co/UvE2ZpxCDU
Links:
Eric Dein ericdeinmd ( View Tweet)
For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD?
(keeping in mind both irAE response and tumor response)
#ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH
@RheumNow
David Liew drdavidliew ( View Tweet)
☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD.
✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48
BUT
✨underpowered
✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082)
✨safety ok
#ACR21 #AbstL10
@RheumNow https://t.co/IxYDE3lN1s
Aurelie Najm AurelieRheumo ( View Tweet)
Safety update for #filgotinib in #RA over ~2.2yrs treatment
👉🏼Well-tolerated with no ne safety concerns since 2020
👉🏼AE incidence rates decreased or remained stable
👉🏼Slight incr rates of NMSC & non-NMSC malignancies
Abs#1698 #ACR21 @RheumNow
https://t.co/0jbZFVgiyN https://t.co/yOlntLwQlU
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD
▶️1 group was initiated into vaccination program vs usual care
⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn
💉programs work!
@Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG
Links:
Eric Dein ericdeinmd ( View Tweet)
Isolated axial involvement exists in 2-5% of PsA patients. In 576 patients 495 (31.4%) had axial disease, of which 32 (2.0%) had isolated axial disease. HLA-B*27+ and lower HAQ scores were associated with isolated axial disease @RheumNow #ACR21 Abst#1775 https://t.co/Y1EAJlA0mT https://t.co/8oZhN3mT30
Dr. Antoni Chan synovialjoints ( View Tweet)
In this study:
💊No correlation bet QTc interval & whole blood HCQ level regardless of dose, CKD or abnormal TTEs in #lupus pts
💊+correlation bet QTci & HCQ levels in pts w/ QTc prolonging drugs but not >456ms
Reassuring, dispels concern on HCQ use
@RheumNow #ACR21 abs1743 https://t.co/kpASRAXJB1
sheila RHEUMarampa ( View Tweet)